Clinical study of intratumoral dendritic cells(DC) injection after radiofrequency ablation(RFA) therapy for the treatment of hepatitis C virus-related hepatocellular carcinoma(HCC) patients
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000000971
- Lead Sponsor
- Tokyo Medical University Hospital
- Brief Summary
Three patients with advanced hepatocellular carcinoma received intratumoral injections of dendritic cells after radiofrequency ablation therapy. In this study, no serious adverse event was observed. The treatment was safe and feasible.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: - Interstitial pneumonia, pulmonary fibrosis, or drug-induced pneumonia , or predisposition to them; - Continuous systemic administration of steroids; - Active autoimmune diseases or predisposition to them; - Other cancers; - Uncontrolled infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Immunological responses, Clinical responses